Download the free e-book on peptides, hormones and pharmaceuticals for longevity, health and performance here: get the e-book
Hair loss is one of the most emotionally charged health topics in the optimization space, and also one of the most misunderstood. The market for hair loss solutions is enormous, the claims made by products in that market are frequently exaggerated, and the actual biology of why hair loss happens and what can be done about it is rarely explained clearly to the people most affected by it.
Understanding the mechanisms behind hair loss makes everything else in this conversation more useful. It tells you why certain treatments work, why they take months to show results, why combining approaches outperforms any single intervention, and what the genuinely new developments in this space actually represent.
The biology of the hair follicle
Hair growth is a cyclical process. Each follicle cycles through three distinct phases repeatedly throughout life. The anagen phase is the active growth phase, during which the hair shaft is actively produced and lengthens. This phase lasts two to seven years in healthy follicles and determines the maximum length hair can grow. The catagen phase is a brief transitional period during which growth stops and the follicle prepares to shed. The telogen phase is the resting phase, after which the hair is shed and the cycle begins again with a new anagen phase.
In healthy follicles, this cycle continues throughout life with each new hair roughly equivalent to the last. In follicles affected by androgenic alopecia, the most common form of hair loss in both men and women, each successive cycle produces a finer, shorter hair than the one before. This process is called miniaturization, and it continues until the follicle eventually stops producing visible hair altogether.
Miniaturization is driven primarily by the action of a hormone called dihydrotestosterone, or DHT, on genetically susceptible follicles.
The DHT mechanism
DHT is derived from testosterone through the action of an enzyme called 5-alpha reductase. In people genetically predisposed to pattern hair loss, hair follicles on the scalp express receptors that are particularly sensitive to DHT. When DHT binds to these receptors it shortens the anagen phase of the hair cycle, making each growth phase progressively briefer and the resulting hair progressively finer, until the follicle can no longer sustain visible hair production.
The genetic predisposition is the variable that determines sensitivity. DHT itself is not inherently problematic. People without the genetic sensitivity can have high DHT levels without experiencing hair loss. People with the sensitivity will experience miniaturization regardless of overall DHT levels, though the rate of progression can be meaningfully influenced by reducing DHT exposure to the affected follicles.
This is the mechanism that DHT blocking medications target.
Finasteride and Dutasteride
Finasteride inhibits one form of the 5-alpha reductase enzyme, reducing DHT production throughout the body. Dutasteride inhibits both forms of the enzyme, producing a more complete reduction in DHT. Both are effective at slowing or stopping the progression of pattern hair loss and in many cases allow miniaturized follicles to partially recover and produce thicker hair over time.
These are among the most effective interventions available for androgenic alopecia and have helped a very large number of people maintain and in some cases recover hair. They are also the interventions that come with the most important risk conversation in this space.
Because DHT plays roles beyond hair follicle signaling, including in libido, sexual function, and mood regulation, reducing it systemically through oral medication affects those systems as well. Most people tolerate these medications without significant side effects. A subset of users experience decreased libido, erectile difficulties, or mood changes. For most, these effects resolve after discontinuation.
A smaller subset of individuals have reported that some symptoms, particularly related to sexual function, persisted after stopping the medication. This is sometimes called post-finasteride syndrome. The frequency and underlying mechanisms of this presentation are not fully understood and remain an area of active research and clinical discussion.
This risk profile does not make these medications inappropriate. It makes them medications that deserve an informed, honest conversation with a provider before starting. Understanding the risk, however small for any individual, and making a decision based on complete information is what this publication is always advocating for.
Topical formulations of both finasteride and minoxidil applied directly to the scalp are increasingly used as an approach that delivers the therapeutic effect locally while reducing systemic absorption and the associated hormonal exposure. For people concerned about systemic effects, this is a meaningful option worth discussing with a provider.
Minoxidil
Minoxidil works through a completely different mechanism than DHT blockers and is complementary rather than redundant. It is a vasodilator that increases blood flow to the scalp, improving oxygen and nutrient delivery to hair follicles. It also extends the anagen phase of the hair cycle, allowing follicles to spend more time in active growth and produce longer, thicker hairs before transitioning to the resting phase.
Minoxidil is available in oral and topical forms and is one of the few hair loss interventions that is effective in both men and women. It does not address the DHT mechanism and therefore does not stop the underlying miniaturization process in androgenic alopecia on its own. Used alongside a DHT blocker, however, it addresses both the cause and the growth phase limitation simultaneously, which is why combination approaches consistently outperform either intervention alone.
GHK-Cu and the scalp environment
GHK-Cu, the copper peptide covered in the longevity and cellular health article in this series for its role in tissue remodeling, has applications in hair health through a related mechanism. Applied topically to the scalp, GHK-Cu supports the structural health of the tissue surrounding hair follicles, promotes collagen synthesis and tissue remodeling in the scalp environment, and has anti-inflammatory properties that may reduce the local inflammatory activity around follicles that contributes to miniaturization.
Its role is complementary rather than primary. It does not block DHT or extend the anagen phase. It supports the follicle environment in ways that may help those primary interventions work more effectively and may independently slow the deterioration of the follicle's structural support.
The emerging frontier: follicle stem cell activation
The most significant development in hair restoration science in recent years involves a fundamentally different approach to the problem. Rather than slowing the loss of existing follicle function, compounds in this category aim to reactivate follicles that have already become dormant.
Hair follicles contain stem cells that retain the capacity to regenerate the follicle and restart the hair growth cycle even after extended periods of dormancy. The question researchers have been working on is what biological signals control the activation and inactivation of these stem cells, and whether those signals can be modulated therapeutically.
JLX-069, a compound available through specialized compounding channels, targets the mitochondrial pyruvate carrier pathway, a metabolic mechanism that regulates the activation state of hair follicle stem cells. By modulating this pathway, JLX-069 aims to shift dormant stem cells back toward an active state, potentially allowing follicles that have stopped producing visible hair to resume production.
This represents a meaningfully different category of intervention from everything else discussed in this article. DHT blockers and minoxidil work on follicles that are still functioning, slowing their decline and supporting their activity. A stem cell activating compound works on follicles that have already stopped, attempting to restore function rather than preserve it.
The clinical evidence base for this approach is still developing, and the compounds in this category should be understood as emerging rather than established. But the mechanism is scientifically sound and the early data is sufficiently compelling that this represents one of the most genuinely exciting developments in hair restoration medicine in decades.
Putting it together
The most effective approach to hair health is layered rather than single-compound, and it is most effective when started early rather than after significant loss has already occurred.
For people experiencing active hair loss driven by androgenic alopecia, a DHT blocker addresses the primary hormonal mechanism. Minoxidil extends the anagen phase and improves follicle blood supply. GHK-Cu supports the follicle environment. And for people who have not responded adequately to conventional approaches or who want to address dormant follicles directly, emerging stem cell activation compounds represent a genuinely new category of option.
The honest message about hair loss is that the biology is better understood than it has ever been, the interventions available are more effective than they have ever been, and the emerging science is more promising than it has ever been. None of this produces overnight results, and none of it works without consistency. But for people who start early and approach it systematically, meaningful preservation and in some cases recovery of hair is achievable in a way that was not possible a generation ago.
This content is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before making any changes to your health regimen. For more information visit www.peakformrx.health